Phenotypic and Genotypic Studies in Congenital and Early Onset Ataxias (ATAXIC)
Congenital ataxias (CA) are rare, non progressive diseases, characterized by psychomotor retardation, hypotonia followed by ataxia. The presence of the "molar tooth" on MRI allowed to define Joubert syndrome, a peculiar form of CA. Apart from this group, CA are mostly associated with cerebellar atrophy or hypoplasia without molar tooth on MRI. CA are a clinically as well as genetically heterogeneous group of diseases. Early-onset ataxias are progressive but may be difficult to distinguish from CA in the first years of the disease. To date, few genes responsible for CA have been identified: ABC7 (X-linked CA associated with sideroblastic anemia), SLC9A6 (X-linked CA associated with severe mental retardation, autism and epilepsy), GPR56 (CA associated with polymicrogyria), ATCAY (pure CA in Cayman isolate); the involvement of the ATCAY and ABC7 genes has never been assessed in a large cohort of CA patients.
To assess the frequency of mutations of the ATCAY and ABC7 genes in patients affected with non Joubert congenital or early-onset ataxia.
To identify new loci and/or genes responsible for CA To further describe the clinical phenotype of the CA and to assess the frequency of the various clinical types (pure CA/CA associated with spasticity/ syndromic CA, congenital/early-onset CA, sporadic/familial CA).
To describe the clinical phenotype of CA related to mutations in one of analysed genes.
Congenital Cerebellar Ataxias
Early-onset Cerebellar Ataxias
Genetic: blood sample
|Study Design:||Observational Model: Family-Based|
|Official Title:||Phenotypic and Genotypic Studies in Congenital and Early Onset Ataxias|
- Percentage of the patients with a mutation in one of the analysed genes. [ Time Frame: 1 day ] [ Designated as safety issue: No ]
- Percentage of patients with severe/moderate/mild/absent intellectual deficiency [ Time Frame: 1 day ] [ Designated as safety issue: No ]
- Percentage of patients with/without epilepsy/spasticity/extraneurological features and nature and frequency of MRI anomalies [ Time Frame: 1 day ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||January 2012|
|Estimated Study Completion Date:||October 2014|
|Estimated Primary Completion Date:||April 2014 (Final data collection date for primary outcome measure)|
Genetic: blood sample
Blood sample will be analysed in order to check presence or not of mutation in ABC7, SLC9A6, GPR56, ATCAY.
Other Name: blood sample
All patients will be examined by a geneticist or a neuropediatric. All clinical data will be collected.
Strategy of the molecular study :
- for all multiplex and consanguineous families a linkage analysis (loci ATCAY and ABC7 and others AC known genes) will be performed.
- For all sporadic patients as well as linked multiplex and consanguineous families : sequencing of all coding exons of the gene ATCAY and others AC known genes.
- For all sporadic male patients and linked families : sequencing of all coding exons of the gene ABC7.
- For all patients with suggestive features : sequencing of all coding exons of the gene GPR56, VLDLR, NHE6 or other candidate gene.
- In consanguineous families : linkage analysis using SNP-array and analysis of candidate genes present in the regions of extended homozygosity
- linkage analysis in dominant families and analysis of candidate genes in the linked regions.
- If a new AC locus is identified (using linkage or CGH array), this gene will be sequenced in all patients.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01488461
|Contact: Lydie Burglen, PhD||+ 33 (0)1 44 73 69 firstname.lastname@example.org|
|Hôpital Trousseau, Service de Génétique||Recruiting|
|Paris, France, 75012|
|Contact: Lydie Burglen, PhD + 33 (0)1 44 73 69 62 email@example.com|
|Principal Investigator:||Lydie Burglen, PhD||Assistance Publique|